|
|
|
|
| LEADER |
01000caa a2200265 4500 |
| 001 |
OLC1979412529 |
| 003 |
DE-627 |
| 005 |
20230714203602.0 |
| 007 |
tu |
| 008 |
160720s2016 xx ||||| 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.bmcl.2016.06.087
|2 doi
|
| 028 |
5 |
2 |
|a PQ20160720
|
| 035 |
|
|
|a (DE-627)OLC1979412529
|
| 035 |
|
|
|a (DE-599)GBVOLC1979412529
|
| 035 |
|
|
|a (PRQ)crossref_primary_10_1016_j_bmcl_2016_06_0870
|
| 035 |
|
|
|a (KEY)0209141020160000000000000000synthesisandbiologicalevaluationofn9substitutedhar
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
4 |
|a 540
|a 610
|q DE-600
|
| 084 |
|
|
|a PHARM
|2 fid
|
| 084 |
|
|
|a VA 2620
|q AVZ
|2 rvk
|
| 100 |
1 |
|
|a Du, Hongtao
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Synthesis and biological evaluation of N9-substituted harmine derivatives as potential anticancer agents
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 700 |
1 |
|
|a Tian, Shan
|4 oth
|
| 700 |
1 |
|
|a Chen, Juncheng
|4 oth
|
| 700 |
1 |
|
|a Gu, Hongling
|4 oth
|
| 700 |
1 |
|
|a Li, Na
|4 oth
|
| 700 |
1 |
|
|a Wang, Junru
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|t Bioorganic & medicinal chemistry letters
|d Amsterdam [u.a.] : Elsevier, 1991
|g (2016)
|w (DE-627)130952400
|w (DE-600)1063195-1
|w (DE-576)025097946
|x 0960-894X
|7 nnns
|
| 773 |
1 |
8 |
|g year:2016
|
| 856 |
4 |
1 |
|u http://dx.doi.org/10.1016/j.bmcl.2016.06.087
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_OLC
|
| 912 |
|
|
|a FID-PHARM
|
| 912 |
|
|
|a SSG-OLC-CHE
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OLC-DE-84
|
| 912 |
|
|
|a SSG-OPC-PHA
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_4305
|
| 936 |
r |
v |
|a VA 2620
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2016
|
